MX2022005624A - Tratamiento de vomito y nausea con una dosis minima de olanzapina. - Google Patents
Tratamiento de vomito y nausea con una dosis minima de olanzapina.Info
- Publication number
- MX2022005624A MX2022005624A MX2022005624A MX2022005624A MX2022005624A MX 2022005624 A MX2022005624 A MX 2022005624A MX 2022005624 A MX2022005624 A MX 2022005624A MX 2022005624 A MX2022005624 A MX 2022005624A MX 2022005624 A MX2022005624 A MX 2022005624A
- Authority
- MX
- Mexico
- Prior art keywords
- olanzapine
- vomiting
- nausea
- treatment
- minimum dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Composiciones, dispositivos y métodos para la administración transdérmica de olanzapina, y usos de los mismos, por ejemplo, para tratar la náusea y el vómito.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062960611P | 2020-01-13 | 2020-01-13 | |
US202062960582P | 2020-01-13 | 2020-01-13 | |
US202063083759P | 2020-09-25 | 2020-09-25 | |
US202063083774P | 2020-09-25 | 2020-09-25 | |
PCT/US2021/013272 WO2021146309A1 (en) | 2020-01-13 | 2021-01-13 | Treatment of vomiting and nausea with minimum dose of olanzapine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005624A true MX2022005624A (es) | 2022-06-14 |
Family
ID=76864221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005624A MX2022005624A (es) | 2020-01-13 | 2021-01-13 | Tratamiento de vomito y nausea con una dosis minima de olanzapina. |
Country Status (9)
Country | Link |
---|---|
US (2) | US11975112B2 (es) |
EP (1) | EP4090333A1 (es) |
JP (1) | JP2023511250A (es) |
KR (1) | KR20220127247A (es) |
CN (1) | CN114901287A (es) |
AU (1) | AU2021207844A1 (es) |
CA (1) | CA3156890A1 (es) |
MX (1) | MX2022005624A (es) |
WO (1) | WO2021146309A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023003350A (es) * | 2020-09-25 | 2023-03-29 | Starton Therapeutics Inc | Tratamiento para el vomito y la nausea con una dosis minima de olanzapina. |
US20240282923A1 (en) | 2021-10-05 | 2024-08-22 | L G Energy Solution, Ltd. | Lithium Secondary Battery |
CN116829131B (zh) * | 2022-01-12 | 2024-05-07 | 新领医药技术(深圳)有限公司 | 奥氮平透皮给药系统及其制备方法和用途 |
CN115252622B (zh) * | 2022-09-26 | 2023-02-21 | 中日友好医院(中日友好临床医学研究所) | 醛糖还原酶阻化剂及其在制备用于治疗肺癌的药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2305860A (en) * | 1996-03-29 | 1997-04-23 | Lilly Co Eli | Anti-emetic |
AU2004291043A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
CN102028695A (zh) * | 2009-09-29 | 2011-04-27 | 北京卓越同创药物研究院 | 奥氮平的用途 |
US20220040194A1 (en) * | 2018-12-17 | 2022-02-10 | Starton Therapeutics, Inc. | Use of olanzapine for treatment of parp-inhibitor-induced nausea |
-
2021
- 2021-01-13 EP EP21704350.4A patent/EP4090333A1/en active Pending
- 2021-01-13 CN CN202180007819.9A patent/CN114901287A/zh active Pending
- 2021-01-13 CA CA3156890A patent/CA3156890A1/en active Pending
- 2021-01-13 MX MX2022005624A patent/MX2022005624A/es unknown
- 2021-01-13 WO PCT/US2021/013272 patent/WO2021146309A1/en unknown
- 2021-01-13 KR KR1020227023552A patent/KR20220127247A/ko unknown
- 2021-01-13 US US17/148,262 patent/US11975112B2/en active Active
- 2021-01-13 AU AU2021207844A patent/AU2021207844A1/en active Pending
- 2021-01-13 JP JP2022539038A patent/JP2023511250A/ja active Pending
-
2024
- 2024-02-20 US US18/581,460 patent/US20240189251A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11975112B2 (en) | 2024-05-07 |
CA3156890A1 (en) | 2021-07-22 |
US20210244679A1 (en) | 2021-08-12 |
JP2023511250A (ja) | 2023-03-17 |
CN114901287A (zh) | 2022-08-12 |
EP4090333A1 (en) | 2022-11-23 |
WO2021146309A1 (en) | 2021-07-22 |
US20240189251A1 (en) | 2024-06-13 |
KR20220127247A (ko) | 2022-09-19 |
AU2021207844A1 (en) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005624A (es) | Tratamiento de vomito y nausea con una dosis minima de olanzapina. | |
PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
MX2021000609A (es) | Métodos de tratamiento con fármacos sustrato para cyp3a4. | |
EA201992722A1 (ru) | N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака | |
MX2009008582A (es) | Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios. | |
MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
BR112021020247A2 (pt) | Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
EP4335517A3 (en) | Administration and dosage of diaminophenothiazines | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
MX2018012719A (es) | Ram negativas para tratar la dermatitis atopica. | |
MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
MX2020001727A (es) | Terapia de combinacion. | |
MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
MX2019013862A (es) | Terapia de combinacion. | |
CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
MX2021000868A (es) | Uso de especies gram negativas para tratar la dermatitis atopica. | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
MX2023003350A (es) | Tratamiento para el vomito y la nausea con una dosis minima de olanzapina. | |
MX2021008716A (es) | Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina. | |
ZA201905212B (en) | Rescue treatment of post operative nausea and vomiting | |
WO2018062876A3 (ko) | 통증이 경감되는 골관절염 치료용 키트 |